首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1563123

全球眼部過敏藥物市場：依類型、藥物類別、治療形式、通路和地區的預測（~2032年）

Global Eye Allergy Treatment Market Research Report Information By Type, By Drug Class, By Treatment Form, By Distribution Channel And By Region Forecast to 2032

出版日期: 2024年08月10日 | 出版商:

Market Research Future | 英文 147 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

眼部過敏藥物的市場規模從2023年的33.5億美元，2024年的35.5億美元，預計2032年將成長到56億2000萬美元，預測期內年複合成長率為6.23%。眼部過敏盛行率的上升、人口老化的加劇以及為滿足高需求而推出的藥物數量不斷增加推動市場成長。

全球眼睛過敏人數的增加推動該市場的擴張。例如，Alcon在2020年 2月估計，大約有 6,600萬美國人患有眼睛過敏。此外，老年人口的增加也推動了市場的發展。據 Senior Home Plus 表示，老年人的眼睛過敏可能是由免疫系統減弱、慢性健康問題、淚液產生減少以及某些藥物的副作用引起的。

區域洞察

2023年，北美市佔率最大。預計到2032年，市場規模將達到 19.4億美元，預測期內年複合成長率為 4.29%。同時，亞太地區預計在預測期內將以 7.11%的最高年複合成長率成長。

歐洲佔第二大市場。原因包括眼疾患者數量不斷增加、先進治療設施的可用性、醫療費用的增加、先進治療方法的引進以及強大的醫療基礎設施的存在。此外，越來越多的政府措施也刺激了市場擴張。此外，老年人口的增加也推動了市場的發展。

亞太地區是一個快速成長的地區。龐大的患者群體、快速的技術進步和市場發展前景促進該地區的市場成長。此外，老年人口的增加也推動了市場的發展。

本報告調查了全球眼過敏治療藥物市場，提供市場的定義和概述，市場成長的各種影響因素分析，市場規模推移和預測，各種區分、地區的細分，競爭環境，主要企業概況等彙整資料。

Global Eye Allergy Treatment Market Research Report Information By Type (Seasonal and Perennial Allergic Conjunctivitis, Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, Contact Allergic Conjunctivitis, Giant Papillary Conjunctivitis), By Drug Class (Antihistamine, Mast Cell Stabilizer, NASAIDs, Corticosteroid, Decongestants, Immunotherapy Allergy Shots, Others), By Treatment Form (Eyedrops, Injectables, Tablets & Capsules), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies) And By Region Forecast to 2032

Market Overview

In 2023, the market for eye allergy treatments was estimated to be worth USD 3.35 billion. The market is expected to expand from USD 3.55 billion in 2024 to USD 5.62 billion by 2032, representing a compound annual growth rate (CAGR) of 6.23% over the forecast period (2024-2032). The rising prevalence of ocular allergies, an expanding geriatric population, and increased medicine launches to fulfill high demand are driving market expansion.

The growing frequency of eye allergies around the world is driving the expansion of the Eye Allergy Treatment Market. For example, in February 2020, Alcon, a Novartis AG (US) firm, estimated that approximately 66 million Americans have ocular allergies. Furthermore, the growing senior population is driving the eye allergy treatment market. According to Senior Home Plus (UK), eye allergies in the older population are caused by a compromised immune system, chronic health issues, decreased tear production, and some drug adverse effects. The market is poised for tremendous development. For example, according to the World Population Prospects 2022, the population above the age of 65 is expanding faster than the population below that age. Furthermore, it has been anticipated that the share of the global population aged 65 and up will increase from 10% in 2022 to 16% by 2050. Furthermore, the growing senior population in Asia-Pacific will provide profitable growth prospects in the coming years. According to the Asia-Pacific Report on Population Ageing 2022, Asia-Pacific had roughly 670 million persons aged 60 and up in 2022. Thus, the increasing prevalence of eye allergies, as well as the growing senior population, are driving global market expansion.

Market Segment insights

The Eye Allergy Treatment Market is divided into five types: seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis.

The Eye Allergy Treatment Market is divided into pharmacological classes, including antihistamines, mast cell stabilizers, NSAIDS, corticosteroids, decongestants, immunotherapy allergy shots, and others.

The Eye Allergy Treatment Market is divided into three segments based on treatment form: eyedrops, injectables, and tablets/capsules.

The Eye Allergy Treatment Market is divided into three distribution channels: hospital pharmacies, internet pharmacies, and retail pharmacies.

Regional insights

The Eye Allergy Treatment Market has been classified by region: North America, Europe, Asia-Pacific, and the Rest of the World. North America had the biggest market share in 2023 and is expected to reach USD 1.94 billion by 2032, representing a CAGR of 4.29% over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 7.11% over the projection period.

The Americas region is followed by Europe, which accounted for the second largest eye allergy treatment market share due to an increasing patient population with eye disorders, the availability of advanced treatment facilities, rising healthcare expenditure, the introduction of advanced therapies into the market, and the presence of a strong healthcare infrastructure. In addition, increased government initiatives are fueling market expansion. Furthermore, the growing senior population is driving the eye allergy treatment market.

Asia-Pacific is the fastest-growing region for Eye Allergy Treatment Market. The presence of a large patient population, quick technological advancement, and numerous prospects for market development all contribute to the growth of the Asia-Pacific eye allergy treatment market. Furthermore, the growing geriatric population is driving the market for eye allergy treatments in this region.

Major Players

Major participants in the Eye Allergy Treatment Market include Johnson & Johnson Services, Inc., Abbvie Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Hal Allergy B.V., Novartis AG, Bausch + Lomb, Santen Pharmaceutical Co., Ltd., Alcon, and Bayer AG.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TECHNIQUE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 RISING PREVALENCE OF EYE ALLERGY AND EXPANDING GERIATRIC POPULATION
- 4.2.2 SURGING DRUG LAUNCHES IN ORDER TO MEET HIGH DEMAND
4.3 RESTRAINTS
- 4.3.1 LACK OF AWARENESS ASSOCIATED WITH CONJUNCTIVITIS
4.4 OPPORTUNITY
- 4.4.1 ONGOING CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL EYE ALLERGY TREATMENT MARKET

6 GLOBAL EYE ALLERGY TREATMENT MARKET, BY TYPE

6.1 OVERVIEW
6.2 SEASONAL AND PERENNIAL ALLERGIC CONJUNCTIVITIS
6.3 VERNAL KERATOCONJUNCTIVITIS
6.4 ATOPIC KERATOCONJUNCTIVITIS
6.5 CONTACT ALLERGIC CONJUNCTIVITIS
6.6 GIANT PAPILLARY CONJUNCTIVITIS

7 GLOBAL EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS

7.1 OVERVIEW
7.2 ANTIHISTAMINE
7.3 MAST CELL STABILIZER
7.4 NSAIDS
7.5 CORTICOSTEROID
7.6 DECONGESTANTS
7.7 IMMUNOTHERAPY ALLERGY SHOTS
- 7.7.1 SUBCUTANEOUS IMMUNOTHERAPY ALLERGY SHOTS TREATMENT (SCIT)
- 7.7.2 SUBLINGUAL IMMUNOTHERAPY ALLERGY SHOTS TREATMENT (SLIT)
7.8 OTHERS

8 GLOBAL EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM

8.1 OVERVIEW
8.2 EYEDROPS
8.3 INJECTABLES
8.4 TABLETS & CAPSULES

9 GLOBAL EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 ONLINE PHARMACY
9.4 RETAIL PHARMACY

10 GLOBAL EYE ALLERGY TREATMENT MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
- 10.4.1 CHINA
- 10.4.2 INDIA
- 10.4.3 JAPAN
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS,
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL

12 COMPANY PROFILES

12.1 JOHNSON & JOHNSON SERVICES, INC
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 ABBVIE INC.
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGY
12.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGIES
12.5 HAL ALLERGY B.V.
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
12.6 NOVARTIS AG
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
12.7 BAUSCH + LOMB
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
12.8 SANTEN PHARMACEUTICAL CO., LTD.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 KEY STRATEGIES
12.9 ALCON
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 BAYER AG
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

簡介目錄圖表

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 3 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR SEASONAL AND PERENNIAL ALLERGIC CONJUNCTIVITIS, BY REGION, 2021-2032 (USD MILLION)
TABLE 4 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR VERNAL KERATOCONJUNCTIVITIS, BY REGION, 2021-2032 (USD MILLION)
TABLE 5 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR ATOPIC KERATOCONJUNCTIVITIS, BY REGION, 2021-2032 (USD MILLION)
TABLE 6 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR CONTACT ALLERGIC CONJUNCTIVITIS, BY REGION, 2021-2032 (USD MILLION)
TABLE 7 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR GIANT PAPILLARY CONJUNCTIVITIS, BY REGION, 2021-2032 (USD MILLION)
TABLE 8 GLOBAL EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 9 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR ANTIHISTAMINE, BY REGION, 2021-2032 (USD MILLION)
TABLE 10 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR MAST CELL STABILIZER, BY REGION, 2021-2032 (USD MILLION)
TABLE 11 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR NSAIDS, BY REGION, 2021-2032 (USD MILLION)
TABLE 12 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR CORTICOSTEROID, BY REGION, 2021-2032 (USD MILLION)
TABLE 13 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR DECONGESTANTS, BY REGION, 2021-2032 (USD MILLION)
TABLE 14 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY REGION, 2021-2032 (USD MILLION)
TABLE 15 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2021-2032 (USD MILLION)
TABLE 16 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR SUBCUTANEOUS IMMUNOTHERAPY ALLERGY SHOTS TREATMENT (SCIT), BY REGION, 2021-2032 (USD MILLION)
TABLE 17 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR SUBLINGUAL IMMUNOTHERAPY ALLERGY SHOTS TREATMENT (SLIT), BY REGION, 2021-2032 (USD MILLION)
TABLE 18 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2032 (USD MILLION)
TABLE 19 GLOBAL EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 20 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR EYEDROPS, BY REGION, 2021-2032 (USD MILLION)
TABLE 21 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR INJECTABLES, BY REGION, 2021-2032 (USD MILLION)
TABLE 22 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR TABLETS & CAPSULES, BY REGION, 2021-2032 (USD MILLION)
TABLE 23 GLOBAL EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 24 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2032 (USD MILLION)
TABLE 25 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR ONLINE PHARMACY, BY REGION, 2021-2032 (USD MILLION)
TABLE 26 GLOBAL EYE ALLERGY TREATMENT MARKET, FOR RETAIL PHARMACY, BY REGION, 2021-2032 (USD MILLION)
TABLE 27 GLOBAL EYE ALLERGY TREATMENT MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 28 NORTH AMERICA: EYE ALLERGY TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 29 NORTH AMERICA: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 30 NORTH AMERICA: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 31 NORTH AMERICA: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 32 NORTH AMERICA: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 33 NORTH AMERICA: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 34 US: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 35 US: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 36 US: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 37 US: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 38 US: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 39 CANADA: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 40 CANADA: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 41 CANADA: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 42 CANADA: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 43 CANADA: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 44 EUROPE: EYE ALLERGY TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 45 EUROPE: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 46 EUROPE: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 47 EUROPE: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 48 EUROPE: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 49 EUROPE: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 50 GERMANY: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 51 GERMANY: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 52 GERMANY: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 53 GERMANY: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 54 GERMANY: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 55 FRANCE: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 56 FRANCE: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 57 FRANCE: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 58 FRANCE: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 59 FRANCE: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 60 UK: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 61 UK: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 62 UK: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 63 UK: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 64 UK: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 65 ITALY: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 66 ITALY: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 67 ITALY: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 68 ITALY: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 69 ITALY: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 70 SPAIN: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 71 SPAIN: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 72 SPAIN: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 73 SPAIN: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 74 SPAIN: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 75 REST OF EUROPE: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 76 REST OF EUROPE: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 77 REST OF EUROPE: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 78 REST OF EUROPE: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 79 REST OF EUROPE: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 80 ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 81 ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 82 ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 83 ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 84 ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 85 ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 86 CHINA: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 87 CHINA: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 88 CHINA: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 89 CHINA: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 90 CHINA: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 91 INDIA: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 92 INDIA: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 93 INDIA: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 94 INDIA: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 95 INDIA: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 96 JAPAN: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 97 JAPAN: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 98 JAPAN: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 99 JAPAN: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 100 JAPAN: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 101 AUSTRALIA: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 102 AUSTRALIA: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 103 AUSTRALIA: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 104 AUSTRALIA: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 105 AUSTRALIA: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 106 SOUTH KOREA: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 107 SOUTH KOREA: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 108 SOUTH KOREA: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 109 SOUTH KOREA: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 110 SOUTH KOREA: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 111 REST OF ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 112 REST OF ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 113 REST OF ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 114 REST OF ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 115 REST OF ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 116 REST OT THE WORLD: EYE ALLERGY TREATMENT MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 117 REST OF THE WORLD: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 118 REST OF THE WORLD: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 119 REST OF THE WORLD: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 120 REST OF THE WORLD: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 121 REST OF THE WORLD: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 122 MIDDLE EAST: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 123 MIDDLE EAST: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 124 MIDDLE EAST: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 125 MIDDLE EAST: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 126 MIDDLE EAST: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 127 AFRICA: EYE ALLERGY TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 128 AFRICA: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 129 AFRICA: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 130 AFRICA: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 131 AFRICA: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 132 LATIN AMERICA: EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD MILLION)
TABLE 133 LATIN AMERICA: EYE ALLERGY TREATMENT MARKET, FOR IMMUNOTHERAPY ALLERGY SHOTS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 134 LATIN AMERICA: EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2019-2032 (USD MILLION)
TABLE 135 LATIN AMERICA: EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 136 PUBLIC PLAYERS STOCK SUMMARY
TABLE 137 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 138 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 139 JOHNSON & JOHNSON SERVICES, INC: PRODUCTS OFFERED
TABLE 140 ABBVIE INC.: PRODUCTS OFFERED
TABLE 141 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED
TABLE 142 SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 143 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED.
TABLE 144 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
TABLE 145 HAL ALLERGY B.V.: PRODUCT OFFERED
TABLE 146 NOVARTIS AG: PRODUCT OFFERED
TABLE 147 BAUSCH + LOMB: PRODUCT OFFERED
TABLE 148 BAUSCH + LOMB: KEY DEVELOPMENTS
TABLE 149 SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT OFFERED
TABLE 150 SANTEN PHARMACEUTICAL CO., LTD.: KEY DEVELOPMENTS
TABLE 151 ALCON: PRODUCT OFFERED
TABLE 152 ALCON: KEY DEVELOPMENTS
TABLE 153 BAYER AG: PRODUCT OFFERED

LIST OF FIGURES

FIGURE 1 GLOBAL EYE ALLERGY TREATMENT MARKET: STRUCTURE
FIGURE 2 GLOBAL EYE ALLERGY TREATMENT MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL EYE ALLERGY TREATMENT MARKET
FIGURE 6 GLOBAL EYE ALLERGY TREATMENT MARKET; TYPE SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 7 GLOBAL EYE ALLERGY TREATMENT MARKET, BY TYPE, 2022 & 2032 (USD MILLION)
FIGURE 8 GLOBAL EYE ALLERGY TREATMENT MARKET SHARE (%), BY TYPE,
FIGURE 9 GLOBAL EYE ALLERGY TREATMENT MARKET; DRUG CLASS SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 10 GLOBAL EYE ALLERGY TREATMENT MARKET, BY DRUG CLASS, 2022 & 2032 (USD MILLION)
FIGURE 11 GLOBAL EYE ALLERGY TREATMENT MARKET SHARE (%), BY DRUG CLASS,
FIGURE 12 GLOBAL EYE ALLERGY TREATMENT MARKET; TREATMENT FORM SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 13 GLOBAL EYE ALLERGY TREATMENT MARKET, BY TREATMENT FORM, 2022 & 2032 (USD MILLION)
FIGURE 14 GLOBAL EYE ALLERGY TREATMENT MARKET SHARE (%), BY TREATMENT FORM,
FIGURE 15 GLOBAL EYE ALLERGY TREATMENT MARKET; DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 16 GLOBAL EYE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2032 (USD MILLION)
FIGURE 17 GLOBAL EYE ALLERGY TREATMENT MARKET SHARE (%), BY DISTRIBUTION CHANNEL,
FIGURE 18 GLOBAL EYE ALLERGY TREATMENT MARKET, BY REGION, 2022 & 2032 (USD MILLION)
FIGURE 19 GLOBAL EYE ALLERGY TREATMENT MARKET SHARE (%), BY REGION,
FIGURE 20 NORTH AMEICA MARKET ANALYSIS: EYE ALLERGY TREATMENT MARKET, 2019-2032 (USD MILLION)
FIGURE 21 NORTH AMERICA: EYE ALLERGY TREATMENT MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION)
FIGURE 22 NORTH AMERICA: EYE ALLERGY TREATMENT MARKET SHARE (%), BY COUNTRY,
FIGURE 23 EUROPE MARKET ANALYSIS: EYE ALLERGY TREATMENT MARKET, 2019-2032 (USD MILLION)
FIGURE 24 EUROPE: EYE ALLERGY TREATMENT MARKET, BY REGION, 2022 & 2032 (USD MILLION)
FIGURE 25 EUROPE: EYE ALLERGY TREATMENT MARKET SHARE (%), BY REGION,
FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: EYE ALLERGY TREATMENT MARKET, 2019-2032 (USD MILLION)
FIGURE 27 ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION)
FIGURE 28 ASIA-PACIFIC: EYE ALLERGY TREATMENT MARKET SHARE (%), BY COUNTRY,
FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: EYE ALLERGY TREATMENT MARKET, 2019-2032 (USD MILLION)
FIGURE 30 REST OT THE WORLD: EYE ALLERGY TREATMENT MARKET, BY REGION, 2022 & 2032 (USD MILLION)
FIGURE 31 REST OT THE WORLD: EYE ALLERGY TREATMENT MARKET SHARE (%), BY REGION,
FIGURE 32 EYE ALLERGY TREATMENT MARKET PLAYERS: COMPETITIVE ANALSIS,
FIGURE 33 COMPETITOR DASHBOARD: GLOBAL EYE ALLERGY TREATMENT MARKET
FIGURE 34 JOHNSON & JOHNSON SERVICES, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 JOHNSON & JOHNSON SERVICES, INC: SWOT ANALYSIS
FIGURE 36 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 ABBVIE INC.: SWOT ANALYSIS
FIGURE 38 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 NOVARTIS AG.: SWOT ANALYSIS
FIGURE 43 BAUSCH + LOMB.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 BAUSCH + LOMB: SWOT ANALYSIS
FIGURE 45 SANTEN PHARMACEUTICAL CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 46 ALCON: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 47 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT